Gardasil for boys is not cost-effective, study says

10/9/2009 | Los Angeles Times (tiered subscription model)

A government campaign to give boys Gardasil, a cervical cancer vaccine that protects against human papillomavirus, would be no more effective in reducing HPV-related diseases and cost much more than a vaccination campaign directed at girls, Harvard University researchers concluded. The findings come as the FDA considers allowing boys to receive Gardasil, made by Merck & Co.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN